On June 23, 2015 SRI International reported cancer drug discovery firm Sareum has received a £140,000 government grant to help the development of a molecule that could be used to treat leukaemia (Press release, SRI International, JUN 23, 2015, View Source [SID:1234505797]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sareum has been given the cash by the UK’s innovation agency, Innovate UK, through its Biomedical Catalyst fund.

The award will allow Sareum to investigate the potential of lead molecules from its TYK2 autoimmune disease programme to treat a strain of leukaemia known as T-ALL, a rare form of the disease that most often occurs in late childhood and early adolescence.

"We are delighted to have won this award from the Biomedical Catalyst, which will give us the opportunity to demonstrate the potential of our TYK2 inhibitors in leukaemia," said Dr Tim Mitchell, CEO of Sareum.